Compositions and methods for inhibiting creatine transport as a treatment for cancer
AssigneeInspirna, Inc.
InventorsMasoud TAVAZOIE, Isabel KURTH, David DARST
Life of this patent
Estimating the term…
Abstract
The disclosure features compositions and methods that are useful for the treatment of cancer (e.g., gastrointestinal, colorectal cancers) featuring creatine transporter inhibitors (e.g., β-Guanidinopropionic acid) in combination with a KRAS inhibitor or another chemotherapeutic agent (e.g., leucovorin (folinic acid-FOL), 5-fluorouracil (F), and irinotecan hydrochloride (IRI), and/or bevacizumab).
Claims22
A method of inhibiting cancer cell proliferation or survival, the method comprising contacting a cancer cell with a creatine transporter inhibitor and a KRAS inhibitor, thereby inhibiting cancer cell proliferation or survival.
A method of inhibiting cancer cell proliferation or survival, the method comprising contacting a cancer cell with β-GPA and Adagrasib, thereby inhibiting cancer cell proliferation or survival.
A method of inhibiting cancer cell proliferation or survival, the method comprising contacting a cancer cell with a creatine transporter inhibitor, FOLFIRI comprising leucovorin (folinic acid-FOL), 5-fluorouracil (F), and irinotecan hydrochloride (IRI), and/or bevacizumab, thereby inhibiting cancer cell proliferation or survival.
A method of treating cancer in a subject, the method comprising administering to the subject a creatine transporter inhibitor and a KRAS inhibitor.
A method of treating a subject having a cancer, the method comprising administering to the subject β-GPA, 5-fluorouracil.
A method of treating cancer in a subject, the method comprising administering to the subject a creatine transporter inhibitor, FOLFIRI comprising leucovorin (folinic acid-FOL), 5-fluorouracil (5-FU), and irinotecan hydrochloride (IRI), and/or bevacizumab.
A method of treating cancer in a subject, the method comprising administering to the subject a creatine transporter inhibitor, and FOLFOX comprising leucovorin (folinic acid-FOL), 5-fluorouracil (5-FU), and oxaliplatin (OX).
A method of treating a selected subject, the method comprising administering to the subject a creatine transporter inhibitor and a KRAS inhibitor, wherein the subject is selected as having a cancer characterized by increased levels of creatine and/or creatine kinase B expression and/or as having a cancer comprising a KRAS, HRAS, or NRAS mutation relative to a control cancer.
A method for treating a subject having cancer, the method comprising administering to the subject β-GPA or a pharmaceutically acceptable salt thereof and FOLinic acid-Fluorouracil-IRInotecan regimen (FOLFIRI), wherein β-GPA or its salt form is administered two times daily at a dosage of 1000 mg-3600 mg.
Dependencies are inferred from the claim text.